Dean E. Schraufnagel

Cyclophosphamide versus Placebo in Scleroderma Lung Disease

Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements et al. · New England Journal of Medicine · 2006 · 1.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Donald P. Tashkin, Michael D. Roth, Philip J. Clements et al. · The Lancet Respiratory Medicine · 2016 · 1.1K citations

Medicine, Pharmacology, Pharmacotherapy +11

The Global Burden of Respiratory Disease

Thomas Ferkol, Dean E. Schraufnagel · Annals of the American Thoracic Society · 2014 · 733 citations

Public Health, Health Policy, Preventive Medicine +17

Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease

Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements et al. · American Journal of Respiratory and Critical Care Medicine · 2007 · 464 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Racial Difference in Sarcoidosis Mortality in the United States

Mehdi Mirsaeidi, Roberto F. Machado, Dean E. Schraufnagel et al. · CHEST Journal · 2014 · 250 citations · Full text

Public Health, Pathology, Clinical Epidemiology +8